Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Volumetric and Functional Regeneration of Remnant Liver With Massive Ascites After Hepatectomy.
Inoue Y, Ishii M, Fujii K, Tomioka A, Yamaguchi T, Yokohama K, Ohama H, Hamamoto H, Osumi W, Tsuchimoto Y, Terazawa T, Ogura T, Masubuchi S, Yamamoto M, Imoto A, Asai A, Fukunishi S, Goto M, Okuda J, Higuchi K, Uchiyama K. Inoue Y, et al. Among authors: ohama h. Am Surg. 2022 Jun;88(6):1369-1373. doi: 10.1177/0003134820947392. Epub 2020 Sep 11. Am Surg. 2022. PMID: 32915056 No abstract available.
Renal Cell Carcinoma and Hepatocellular Carcinoma in a Patient with Wilson's Disease.
Kitahata S, Michitaka K, Kinebuchi M, Matsuura A, Hiraoka A, Ohama H, Yanagihara E, Saneto H, Izumoto H, Kawamura T, Kuroda T, Tada F, Miyata H, Ninomiya T, Hiasa Y. Kitahata S, et al. Among authors: ohama h. Intern Med. 2024 Apr 1;63(7):963-968. doi: 10.2169/internalmedicine.2056-23. Epub 2023 Aug 23. Intern Med. 2024. PMID: 37612087 Free PMC article.
Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.
Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Ohama H, et al. Oncology. 2023;101(9):575-583. doi: 10.1159/000530987. Epub 2023 Jul 17. Oncology. 2023. PMID: 37459848 Free PMC article.
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era.
Nakamura Y, Hirooka M, Hiraoka A, Koizumi Y, Yano R, Morita M, Okazaki Y, Imai Y, Ohama H, Hirooka K, Watanabe T, Tada F, Yoshida O, Tokumoto Y, Abe M, Hiasa Y. Nakamura Y, et al. Among authors: ohama h. Cancers (Basel). 2023 Nov 6;15(21):5298. doi: 10.3390/cancers15215298. Cancers (Basel). 2023. PMID: 37958471 Free PMC article.
Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma.
Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hanaoka J, Watanabe J, Ohtani H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Ohama H, et al. Cancers (Basel). 2022 Dec 30;15(1):236. doi: 10.3390/cancers15010236. Cancers (Basel). 2022. PMID: 36612233 Free PMC article.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
Ohama H, Hiraoka A, Tada T, Kariyama K, Itobayashi E, Tsuji K, Ishikawa T, Toyoda H, Hatanaka T, Kakizaki S, Naganuma A, Tada F, Tanaka H, Nakamura S, Nouso K, Tanaka K, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Ohama H, et al. J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553. Online ahead of print. J Gastroenterol Hepatol. 2024. PMID: 38602340
Simple method for predicting muscle volume loss using geriatric nutritional risk index in hepatocellular carcinoma patients.
Hiraoka A, Ohama H, Tada F, Fukunishi Y, Yanagihara E, Kato K, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Hiraoka A, et al. Among authors: ohama h. J Cachexia Sarcopenia Muscle. 2023 Aug;14(4):1906-1911. doi: 10.1002/jcsm.13268. Epub 2023 May 19. J Cachexia Sarcopenia Muscle. 2023. PMID: 37203385 Free PMC article. No abstract available.
mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
Tada T, Kumada T, Hiraoka A, Kariyama K, Yasuda S, Tada F, Ohama H, Nouso K, Matono T, Nakamura S, Toyoda H; Real-life Practice Experts for HCC (RELPEC) Study Group. Tada T, et al. Among authors: ohama h. J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512. Online ahead of print. J Gastroenterol Hepatol. 2024. PMID: 38403468
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Among authors: ohama h. Hepatol Res. 2023 Feb;53(2):116-126. doi: 10.1111/hepr.13852. Epub 2022 Nov 16. Hepatol Res. 2023. PMID: 36316794
132 results